<scp>BK</scp> viremia surveillance and outcomes in simultaneous pancreas‐kidney transplant recipients

Westphal, Scott G.; Lyden, Elizabeth; Langewisch, Eric; Miles, Clifford D.

doi:10.1111/ctr.13010

Cited by 9 publications

(10 citation statements)

References 24 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourteen studies included adequate data to calculate the proportion of late BKPyVAN, defined as >1 year post‐transplant (Table ) . Among studies evaluating KTRs, 36.4% of BKPyVAN (27 of 74) occurred late (median 9.1 months post‐transplant, range 1‐113 months).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and outcomes of late‐onset BK virus nephropathy in kidney and kidney‐pancreas transplant recipients

Imlay

Whitaker

Fisher

et al. 2018

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…An independent analysis of time to diagnosis of BKPyVAN was performed for all evaluable studies. Only those cohort studies in which the proportion of late‐ and early‐onset BKPyVAN could be accurately determined based on the data provided in the published paper were included in Table …”

Section: Methodsmentioning

confidence: 99%

Clinical characteristics and outcomes of late‐onset BK virus nephropathy in kidney and kidney‐pancreas transplant recipients

Imlay

Whitaker

Fisher

et al. 2018

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…However, it can be removed as an initial therapeutic measure along with the reduction of the CI dose 52 , as the administration of antimetabolite mycophenolate leads to an increase in the incidence of BKV viruria 24 . Even in patients after concomitant renal and pancreatic transplantation, reduction of immunosuppression in BKV viraemia and BKVN seems to be an effective and efficient method of preventing deterioration of renal function, without influencing the prognosis of pancreatic graft 78 .…”

Section: Bkvn Screening and Prophylaxismentioning

confidence: 99%

BK virus-induced renal allograft nephropathy

Krejčí¹,

Tichý²,

Bednaříková³

et al. 2018

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

BK virus nephropathy (BKVN) is a serious opportunistic infection threatening renal function especially during the first year after transplantation. Its incidence is now on the rise and is closely related to the level of the recipient's immune system inhibition. This is more intensive with current trends in transplantation medicine, where more potent immunosuppressive protocols are used and more aggressive antirejection therapy is applied. In the absence of BK virus (BKV) specific therapy and limited treatment options for advanced BKVN, active screening of BKV replication and subsequent preemptive adjustment of immunosuppression are essential measures to prevent BKVN. However, it remains unclear how to modify immunosuppressive protocols as well as how to address initial stages of BKV replication. This comprehensive review summarizes the currently applied and not completely uniform procedures for the detection, prophylaxis and therapy of BKV replication and BKVN. The pitfalls brought by reduced immunosuppression, as a typical response to a significant viral replication or a developed BKVN, are also mentioned, particularly in the form of graft rejection. The paper also outlines the authors' experiences, and lists currently ongoing studies on the subject. The perspectives of new, especially immune-based, procedures in the treatment of complications associated with BKV infections are highlighted. Different views on the management of patients indicated for kidney re-transplantation whose previous graft failed because of BKVN are also discussed.

show abstract

“…The basic treatment strategy is immunosuppressive drug tapering, which is currently the recommended treatment of BKV viremia after kidney transplantation, 5 and using immunosuppressive drugs with antiviral properties are under evaluation. 6 The inhibitors of the mammalian target rapamycin (mTOR) also have data supporting their potential use for BKV infections after transplantation.…”

Section: Introductionmentioning

confidence: 99%

In vitro anti-BK polyomavirus activity of imidazo[1,2-c]pyrimidine and pyrimido[1,6 a]pyrimidine derivatives

Solomyannyi¹,

Mitiukhin²,

Prichard³

et al. 2020

10.5267/j.ccl

View full text Add to dashboard Cite

Five imidazo[1,2-c]pyrimidine and pyrimido[1,6-a]pyrimidine derivatives were designed, synthesized and evaluated for their antiproliferative activity and cytotoxicity. Primary bioassays in vitro showed that two of five synthesized compounds, 6-benzyl-8-(methylsulfonyl)-2,6-dihydroimidazo[1,2-c]pyrimidin-5(3H)-one, and 9-(methylsulfonyl)-7propyl-2,3,4,7-tetrahydro-6H-pyrimido[1,6-a]pyrimidin-6-one possessed potent antiviral activity against BKV (EC50: 0.66 μM and 0.96, respectively). The selectivity index of these compounds is similar to that of cidofovir. Although antiviral activity was evident in secondary assays, significant virus inhibition occurred at or near the cytotoxic concentration (SI90=1). Here we show that substituted pyrimidine derivatives are a promising structure class of chemical compounds for the development of antiviral drugs against BKV infections. Hence these compounds may be taken as lead compounds for further development of novel antimicrobial and anticancer agents.

show abstract

BK viremia surveillance and outcomes in simultaneous pancreas‐kidney transplant recipients

Abstract: Screening asymptomatic SPK recipients for BKV followed by reduction in maintenance immunosuppression appears to be an effective strategy to prevent kidney allograft dysfunction and graft loss due to BK virus nephropathy, without compromising pancreas allograft outcomes.

Cited by 9 publications

References 24 publications

Clinical characteristics and outcomes of late‐onset BK virus nephropathy in kidney and kidney‐pancreas transplant recipients

Clinical characteristics and outcomes of late‐onset BK virus nephropathy in kidney and kidney‐pancreas transplant recipients

BK virus-induced renal allograft nephropathy

In vitro anti-BK polyomavirus activity of imidazo[1,2-c]pyrimidine and pyrimido[1,6 a]pyrimidine derivatives

Contact Info

Product

Resources

About